Out of those participants, 85% lost at least 5% of their weight (versus 26% with placebo), 69% lost at least 10% (vs 12%), 54% lost at least 15% (vs 6%), and 34% lost at least 20% (vs 3%)
The FDA has also shared safety information on compounded and counterfeit "semaglutide" on their website here, with the most recent counterfeit report here (April 2025)
Tirzepatide : Combines GLP-1 activity with another hormone, GIP (glucose-dependent insulinotropic polypeptide), enhancing its effects on appetite suppression and metabolic health
Restoration of p53 function leads to tumour regression in vivo
By activating GLP-1 receptors within the mind, semaglutide enables to reduction of starvation, and the growth of emotions of fullness, and therefore lowers normal calorie consumption